34 results on '"Nguyen, Allison Martin"'
Search Results
2. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study
3. Validation and Meaningful Change Thresholds for an Objective Cough Frequency Measurement in Chronic Cough
4. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice
5. Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough
6. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma
7. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
8. Does recall period matter? Comparing PROMIS ® physical function with no recall, 24-hr recall, and 7-day recall
9. Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355.
10. Health-Related Quality of Life With Pembrolizumab+Chemotherapy Versus Placebo+Chemotherapy for Advanced Triple-Negative Breast Cancer: KEYNOTE-355
11. A phase 2b multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of vaginal rings containing nomegestrol acetate or etonogestrel and 17β-estradiol in the treatment of women with primary dysmenorrhea
12. Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks
13. A qualitative study to develop a patient-reported outcome for dysmenorrhea
14. Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (023)
15. Epidemiology and correlates of osteoporotic fractures among type 2 diabetic patients
16. sj-pdf-1-tar-10.1177_17534666221099737 – Supplemental material for Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough
17. sj-pdf-3-tar-10.1177_17534666221099737 – Supplemental material for Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough
18. sj-pdf-2-tar-10.1177_17534666221099737 – Supplemental material for Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough
19. Comparisons Of Baseline Characteristics And Treatment Efficacy In Individuals With Refractory Or Unexplained Chronic Cough Enrolled In Phase 3 Trials Of Gefapixant
20. Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough
21. Patient-reported chronic cough severity over 52 weeks in two phase 3 trials of gefapixant
22. Predictors of attrition and weight loss success: Results from a randomized controlled trial
23. The Acyclic CB1R Inverse Agonist Taranabant Mediates Weight Loss by Increasing Energy Expenditure and Decreasing Caloric Intake
24. Performance-Based or Self-Report Measures of Physical Function: Which Should Be Used in Clinical Trials of Hip Fracture Patients?
25. Author_Response_1 – Supplemental material for Quantitative measurement properties and score interpretation of the Cough Severity Diary in patients with chronic cough
26. Reviewer_2_v.1 – Supplemental material for Quantitative measurement properties and score interpretation of the Cough Severity Diary in patients with chronic cough
27. Efficacy and safety of gefapixant, a P2X3receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
28. Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial
29. A qualitative study to develop a patient-reported outcome for dysmenorrhea
30. Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy
31. Poster 68: Utility of Self-Report and Performance-Based Measures of Physical Function in Clinical Trials
32. Effect of NPY5R Antagonist MK-0557 on Weight Regain after Very-low-calorie Diet-induced Weight Loss*
33. Neoadjuvant pembrolizumab+chemotherapy/adjuvant pembrolizumab for Early-Stage Triple-Negative breast cancer: Quality-of-Life results from randomized KEYNOTE-522 study.
34. Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.